Outpace Bio raises $144M Series B funding, led by RA Capital Management, to advance their cell therapy targeting platinum-resistant ovarian cancer.

Outpace Bio, a Seattle-based cell therapy company using AI for protein design to target solid tumors, raised $144M in Series B funding led by RA Capital Management. Funds will be used to advance their programmed T cell product candidates, with lead program OPB-101 targeting platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The treatment is on track for IND clearance and first dosing in 2025.

August 01, 2024
3 Articles

Further Reading